Bridgebio Pharma

Manufacturing · California, United States · 501-1,000 Employees

View Company Info for Free

Overview

Headquarters

3160 Porter Dr Ste 250, Palo Alto, Calif...

Phone Number

(650) 391-9740

Revenue

$580 Million

Stock Symbol

BBIO

Industry

Manufacturing Pharmaceuticals
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
7
1
2
2
2

About Bridgebio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Explore more
Bridgebio Pharma's Social MediaPopular SearchesBridgeBio Pharma IncBridgeBioBridgeBio PharmaBridgeBio Pharma LLCBridgeBio IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: BBIOShow more

Bridgebio Pharma Org Chart

PhoneEmail
JE
United States flag for contact location.

Chief Operating Officer, Skeletal Dysplasias

Flame icon indicating likelihood to engage via phone.PhoneFlame icon indicating likelihood to engage via email.Email
TT
United States flag for contact location.

President & Chief Financial Officer

Flame icon indicating likelihood to engage via phone.PhoneFlame icon indicating likelihood to engage via email.Email
JJ
United States flag for contact location.

Chief Technology Officer

PhoneEmail
Ricardo Panicucci, Chief Technology Officer, CMC at Bridgebio Pharma
United States flag for contact location.

Chief Technology Officer, CMC

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
DO
United States flag for contact location.

Vice President, Affairs & Sciences, Gene Ther...

PhoneEmail
JH
United States flag for contact location.

Senior VP, Quality & Compliance

Flame icon indicating likelihood to engage via phone.PhoneFlame icon indicating likelihood to engage via email.Email
TB
United States flag for contact location.

Senior VP, Clinical Development Operations

PhoneEmail
LK
United States flag for contact location.

Senior VP, Clinical Development

PhoneEmail
PB
United States flag for contact location.

Senior VP, Clinical Development Operations

PhoneEmail
TB
United States flag for contact location.

Vice President, Clinical Quality Assurance

PhoneEmail
BW
United States flag for contact location.

Vice President, Supply Chain

PhoneEmail
MT
United States flag for contact location.

Compliance Vice President, People Operations

Flame icon indicating likelihood to engage via phone.PhoneFlame icon indicating likelihood to engage via email.Email
KP
United States flag for contact location.

Vice President, Strategic Alliances

PhoneEmail
JH
United States flag for contact location.

Vice President

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Bridgebio Pharma your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Bridgebio Pharma

Compare insights from companies similar to Bridgebio Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Bridgebio Pharma

$580M
501-1,000
Public
$2B
2015
JE
Julie EverettChief Operating Officer, Skeletal Dysplasias
$796.3M
201-500
Public
$1.1B
2002
Vikram Karnani, President & Chief Executive Officer at Collegium Pharmaceutical
Vikram KarnaniPresident & CEO
$285.6M
501-1,000
Public
$1.1B
2007
Frederick Vogt, Interim Chief Executive Officer & General Counsel at Iovance Biotherapeutics
Frederick VogtInterim CEO & General Counsel
$217.8M
501-1,000
Public
$57.5M
2003
$164M
501-1,000
Public
$1.3B
2017
$17.9M
201-500
Private
-
2003
SV
Suchi VermaHead of HR, Organisation
501-1,000
Public
$1.3B
2014
KT
Karen TynanOwner & CEO
Illustration of an envelopeCompany Insights

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Bridgebio Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Bridgebio Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bridgebio Pharma.

Bridgebio Pharma financials insights

Gather financial insights about Bridgebio Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2017

Multiple Rounds

$174.7M

2019

Other Financing Round

$299.2M

2020

Debt

$475M

2021

Debt

$750M

2025

Other Financing Round

$300M

See All Bridgebio Pharma's Financials Insights

Bridgebio Pharma Tech Stack

A closer look at the technologies used by Bridgebio Pharma

Most Recent Scoops

Hiring Plans
Bridgebio Pharma has more open roles in Finance than it has had at any time in the past 9 months. Areas of expertise include: Financial Risk, Treasury Operations, Cash Management, Bank Reconciliations, Trade Finance, Treasury Management, and Debt Management Planning.
Hiring Plans
Hiring Plans
Bridgebio Pharma has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: Remote, BetterUp, and Spring Health. Areas of expertise include: Change Control, Regulatory Requirements, and Regulatory CMC.
Hiring Plans
Hiring Plans
Bridgebio Pharma has more open roles in Sales than it has had at any time in the past 12 months. Areas of expertise include: Sales Operations.
Hiring Plans
Open Position
Open Position
See more scoops

Top Manufacturing Companies

Frequently Asked Questions Regarding Bridgebio Pharma

What is Bridgebio Pharma's stock symbol?
Bridgebio Pharma's stock symbol is BBIO
What is Bridgebio Pharma's official website?
Bridgebio Pharma's official website is www.bridgebio.com
What is Bridgebio Pharma's Revenue?
Bridgebio Pharma's revenue is $580 Million
What is Bridgebio Pharma's SIC code?
Bridgebio Pharma's SIC: 28,283
What is Bridgebio Pharma's NAICS code?
Bridgebio Pharma's NAICS: 32,325
How many employees does Bridgebio Pharma have?
Bridgebio Pharma has 501-1,000 employees
What industry does Bridgebio Pharma belong to?
Bridgebio Pharma is in the industry of: Manufacturing, Pharmaceuticals
What is Bridgebio Pharma competition?
Bridgebio Pharma top competitors include: Denali Therapeutics, DNDi, Iovance Biotherapeutics, Vanda Pharmaceuticals
What companies has Bridgebio Pharma acquired?
Bridgebio Pharma has acquired the companies: Eidos Therapeutics
What technology does Bridgebio Pharma use?
Some of the popular technologies that Bridgebio Pharma uses are: Freshservice, Zingfit, WordPress.org, Optimizely
Who is the CFO of Bridgebio Pharma?
Bridgebio Pharma's CFO is Thomas Trimarchi
Who is the CTO of Bridgebio Pharma?
Bridgebio Pharma's CTO is Jesper Jernelius
How do I contact Bridgebio Pharma?
Bridgebio Pharma contact info: Phone number: (650) 391-9740 Website: www.bridgebio.com
What does Bridgebio Pharma do?

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Read More

What are Bridgebio Pharma social media links?
Bridgebio Pharma Linkedin page Bridgebio Pharma Twitter page
Who invested in Bridgebio Pharma?
Bridgebio Pharma has 16 investors including Cormorant Asset Management, Perceptive Advisors, KKR and Neil Kumar.
Is Bridgebio Pharma a public company?
Yes, Bridgebio Pharma is a public company and is traded under the symbol BBIO
See more information about Bridgebio Pharma

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.